Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes
Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes
Insulin-like growth factor-I (IGF-I) is abused by elite athletes for its metabolic and anabolic effects. We have previously shown that it is possible to detect IGF-I misuse by measuring serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) but a pilot study suggested measuring IGF-II, IGF binding protein-2 (IGFBP-2) and acid-labile subunit (ALS) may improve the detection of IGF-I administration. The aim of the study was to assess this in a randomized controlled trial. Twenty-six female and 30 male recreational athletes were randomized to 28?days’ treatment with placebo or recombinant human (rh)IGF-I/rhIGF binding protein-3 (IGFBP-3) complex (30?mg/day or 60?mg/day), followed by 56?days’ washout. IGF-II, IGFBP-2 and ALS (women only) were measured using commercial immunoassays. IGFBP-2 increased and IGF-II decreased in response to both low and high dose rhIGF-I/rhIGFBP-3 in both women and men while ALS decreased in women in response to high dose rhIGF-I/rhIGFBP-3. Two days after discontinuing treatment, significant differences remained between the three treatment groups in IGFBP-2 and IGF-II, but not ALS. Thereafter there were no significant differences between the three treatment groups in any of the markers. Combining IGF-I with IGF-II and/or IGFBP-2 improved the performance of the test to detect rhIGF-I/rhIGFBP-3 administration in both women and men
Holt, Richard
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Böhning, W.
d862f4db-88a4-4628-b678-96d377264f72
Bartlett, C.
fdad05d5-46a9-44f1-8554-65d78f0c4523
Cowan, D.A.
12cb2fe2-013f-4576-a834-aec644df8a06
Sönksen, P.H.
e2efe20d-b58b-4767-aa12-49f55ed2063a
Böhning, D.
52e66c7f-b1a2-4535-a144-8bdcd7544909
Holt, Richard
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan
38212040-a65e-4874-a60a-21f0ae3bdf09
Böhning, W.
d862f4db-88a4-4628-b678-96d377264f72
Bartlett, C.
fdad05d5-46a9-44f1-8554-65d78f0c4523
Cowan, D.A.
12cb2fe2-013f-4576-a834-aec644df8a06
Sönksen, P.H.
e2efe20d-b58b-4767-aa12-49f55ed2063a
Böhning, D.
52e66c7f-b1a2-4535-a144-8bdcd7544909
Holt, Richard, Guha, Nishan, Böhning, W., Bartlett, C., Cowan, D.A., Sönksen, P.H. and Böhning, D.
(2016)
Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
Drug Testing and Analysis.
(doi:10.1002/dta.1941).
(PMID:26888146)
Abstract
Insulin-like growth factor-I (IGF-I) is abused by elite athletes for its metabolic and anabolic effects. We have previously shown that it is possible to detect IGF-I misuse by measuring serum IGF-I and procollagen type III amino-terminal propeptide (P-III-NP) but a pilot study suggested measuring IGF-II, IGF binding protein-2 (IGFBP-2) and acid-labile subunit (ALS) may improve the detection of IGF-I administration. The aim of the study was to assess this in a randomized controlled trial. Twenty-six female and 30 male recreational athletes were randomized to 28?days’ treatment with placebo or recombinant human (rh)IGF-I/rhIGF binding protein-3 (IGFBP-3) complex (30?mg/day or 60?mg/day), followed by 56?days’ washout. IGF-II, IGFBP-2 and ALS (women only) were measured using commercial immunoassays. IGFBP-2 increased and IGF-II decreased in response to both low and high dose rhIGF-I/rhIGFBP-3 in both women and men while ALS decreased in women in response to high dose rhIGF-I/rhIGFBP-3. Two days after discontinuing treatment, significant differences remained between the three treatment groups in IGFBP-2 and IGF-II, but not ALS. Thereafter there were no significant differences between the three treatment groups in any of the markers. Combining IGF-I with IGF-II and/or IGFBP-2 improved the performance of the test to detect rhIGF-I/rhIGFBP-3 administration in both women and men
Text
DTA-2015-0281Holtetalrevised FINAL.docx
- Accepted Manuscript
More information
Accepted/In Press date: 3 December 2015
e-pub ahead of print date: 17 February 2016
Organisations:
Faculty of Medicine
Identifiers
Local EPrints ID: 394700
URI: http://eprints.soton.ac.uk/id/eprint/394700
ISSN: 1942-7603
PURE UUID: fd5855bf-323e-4adb-b5df-dea343489242
Catalogue record
Date deposited: 20 May 2016 10:33
Last modified: 15 Mar 2024 03:08
Export record
Altmetrics
Contributors
Author:
Nishan Guha
Author:
W. Böhning
Author:
C. Bartlett
Author:
D.A. Cowan
Author:
P.H. Sönksen
Author:
D. Böhning
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics